Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
160actual
Sites
105
Countries
Australia, France, Germany +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-19 | actual | When the study began enrolling |
| Primary completion | 2025-07-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-14 | actual | The whole study's end, after follow-up |
| First posted | 2022-01-20 | actual | When this record first appeared on the registry |
| Results posted | 2026-07-22 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colorectal Cancer (CRC)
Interventions
- Drug: Sotorasib — also filed as AMG 510, Lumakras, Lumykras
- Drug: Panitumumab — also filed as Vectibix
- Drug: Trifluridine and Tipiracil — also filed as Lonsurf
- Drug: Regorafenib — also filed as Stivarga
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR
measured From randomization until DCO or death; median (min, max) time on trial was 6.23 (0.1, 14.0) months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-02-19 · 3.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-12-07 · 1.1 MB · SAP_001.pdf
Publications
- PMID 37870968 — cited as background
- PMID 40215429 — cited as background
- PMID 40812325 — cited as background
- PMID 42173791 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed